When it comes to cosmetic regulation, one statistic is often cited: the European Union has banned or restricted over 1,600 substances in cosmetics, while the United States has formally banned or restricted only a few dozen. This stark contrast has fueled debate about which system better protects consumers. The difference, however, lies less in the number itself and more in the regulatory philosophy and legal framework behind each system.

1. The Precautionary Principle vs. Risk-Based Regulation

The most significant distinction between the EU and U.S. approaches is philosophical.

The European Union operates under the precautionary principle. This principle allows regulators to restrict or ban ingredients if there is credible scientific concern about potential harm—even if the evidence is not yet conclusive. If an ingredient is suspected of being carcinogenic, mutagenic, toxic to reproduction, or disruptive to the endocrine system, EU regulators can prohibit its use until safety is clearly demonstrated.

In contrast, the United States generally follows a risk-based approach. The U.S. Food and Drug Administration (FDA) typically requires substantial evidence of harm before banning or restricting an ingredient. The burden often falls on regulators to prove danger rather than on manufacturers to prove safety beyond doubt.

This philosophical divide alone explains much of the discrepancy in banned substance counts.

2. Pre-Market Approval vs. Post-Market Enforcement

In the EU, cosmetic products and their ingredients are subject to strict pre-market requirements. Manufacturers must prepare a detailed safety assessment conducted by a qualified professional before a product can be sold. Ingredients classified as carcinogenic, mutagenic, or toxic to reproduction (CMRs) are generally prohibited unless specifically exempted under strict conditions.

In the U.S., cosmetics (with the exception of color additives) do not require FDA pre-market approval. Companies are legally responsible for ensuring product safety, but the FDA typically takes action only after a product is found to be unsafe or misbranded. This reactive system can result in fewer formal bans, even when controversial ingredients are widely debated.

3. Centralized Scientific Oversight

The EU relies on the Scientific Committee on Consumer Safety (SCCS), which continuously evaluates ingredients and updates annexes to the EU Cosmetics Regulation. When new scientific data raises concerns, the ingredient may be restricted or banned across all EU member states.

The U.S. lacks a comparably centralized, mandatory scientific review system specifically for cosmetics. While the FDA monitors safety data and can act against unsafe products, the process for banning substances is often slower and more politically complex.

4. Legal Authority and Regulatory History

The EU Cosmetics Regulation (EC) No 1223/2009 provides regulators with broad authority to restrict ingredients proactively. It has been updated regularly to reflect evolving science.

By contrast, U.S. cosmetic law was historically governed by the Federal Food, Drug, and Cosmetic Act of 1938, which remained largely unchanged for decades. Only recently, with the Modernization of Cosmetics Regulation Act (MoCRA) of 2022, has the FDA gained expanded authority over cosmetic oversight. However, the U.S. system still does not mirror the EU’s precautionary structure.

5. Cultural and Political Context

European regulators tend to prioritize consumer and environmental health in regulatory decision-making. Public pressure in the EU often favors stricter controls, particularly regarding endocrine disruptors and potential carcinogens.

In the U.S., regulatory policy traditionally emphasizes balancing safety with economic impact and innovation. This can lead to a higher tolerance for ingredients unless strong evidence demonstrates harm.

The Bottom Line

The EU has more banned cosmetic ingredients not necessarily because products in the U.S. are less safe, but because the EU employs a more precautionary, proactive regulatory framework. The U.S., historically more reactive and risk-based, bans fewer substances unless clear evidence of harm emerges.

As global cosmetic markets continue to align and regulatory reform evolves, particularly in the U.S., the gap between the two systems may narrow. For now, however, the difference reflects two distinct regulatory philosophies rather than a simple measure of safety.